Investors

POZEN Quarterly Results

Aralez Pharmaceuticals | POZEN
YearTitle
2015
POZEN Reports Third Quarter 2015 Results
POZEN Reports Second Quarter 2015 Results
POZEN Reports First Quarter 2015 Results
2014
POZEN Reports Fourth Quarter and Year End 2014 Results
POZEN Reports Third Quarter 2014 Results
POZEN Reports Second Quarter 2014 Results
POZEN Reports First Quarter 2014 Results
2013
POZEN Reports Fourth Quarter & Year End 2013 Results
POZEN Reports Third Quarter 2013 Results
POZEN Reports Second Quarter 2013 Results
POZEN Reports First Quarter 2013 Results
2012
POZEN Reports Fourth Quarter & Year End 2012 Results
POZEN Reports Third Quarter 2012 Financial Results and Positive PA32540 Clinical Updates
POZEN Reports PA32540 / PA8140 Updates and Second Quarter 2012 Financial Results
POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results
2011
POZEN Reports Fourth Quarter & Year End 2011 Results
POZEN Reports Third Quarter 2011 Results
POZEN Reports Second Quarter 2011 Results
POZEN Reports First Quarter 2011 Results
2010
POZEN Reports Fourth Quarter and Year End 2010 Results
POZEN Reports Third Quarter 2010 Results
POZEN Reports Second Quarter Profit; Results Reflect $20 Million Milestone Payment For VIMOVO(TM)
POZEN Reports First Quarter 2010 Results
2009
POZEN Reports Fourth Quarter/Year End 2009 Results
POZEN Reports Third Quarter 2009 Results
POZEN Reports Second Quarter 2009 Results
POZEN Reports First Quarter 2009 Results
2008
POZEN Reports Fourth Quarter and Year End 2008 Results
POZEN Reports Third Quarter 2008 Results
POZEN Reports Second Quarter 2008 Results
POZEN Reports First Quarter 2008 Results
2007
POZEN Reports Fourth Quarter and Year End 2007 Results
POZEN Reports Third Quarter Results
POZEN Reports Second Quarter 2007 Results
POZEN Reports First Quarter 2007 Results
2006
POZEN Reports Fourth Quarter and Year End 2006 Results
POZEN Reports Third Quarter Results
Pozen Reports Second Quarter 2006 Results
POZEN Reports First Quarter 2006 Results
2005
POZEN Reports Fourth Quarter and Year End 2005 Results; $20 Million Milestone Payment from GSK Contributes to Profitability; Lornoxicam Phase II Studies Initiated in Acute Pain And Migraine
Pozen Reports Third Quarter 2005 Results; Trexima(TM) NDA Accepted for Filing by FDA in October
POZEN Reports Second Quarter 2005 Results; Trexima(TM) NDA on Track for Q3 2005 Submission
POZEN Reports First Quarter 2005 Results; Trexima NDA Scheduled for 3Q 2005; Notice of Allowance Received for New Patent Application Describing Gastroprotective NSAID Products
2004
POZEN Reports Fourth Quarter and Year End 2004 Results; Completes First Trexima Phase III Study
POZEN Reports Third Quarter 2004 Results
POZEN Reports Second Quarter Results
POZEN Reports First Quarter 2004 Results
2003
POZEN Reports Fourth Quarter and Full-Year 2003 Results; POZEN Books Revenue and Achieves Positive Cash Flow in 2003
POZEN Reports Third Quarter 2003 Results; POZEN Reports Revenue for the First Time in Company History
POZEN Reports Second Quarter Results; Company Anticipates a Lower Loss for the Year
POZEN Reports First Quarter Results; Data will be presented at the American Headache Society's 45th Annual Scientific Meeting in June
2002
POZEN Reports Fourth Quarter and Full-Year 2002 Results
POZEN Reports Third Quarter 2002 Results
POZEN Reports Second Quarter Results; Company Anticipates a Lower Loss for the Year
POZEN First-Quarter Results Meet Expectations
2001
POZEN Inc. Releases Fourth-Quarter and Full-Year Results That Meet Expectations
POZEN Inc. Releases Third-Quarter Results; Begins Two Clinical Trials
POZEN Inc. Second-Quarter Results Meet Expectations
POZEN Inc. First-Quarter Results Meet Expectations; Initiates Six-Month Mouse Carcinogenicity Study; Announces Positive Results for Mt 400 Study
2000
POZEN Inc. Reports Fourth-Quarter and Full-Year Results That Meet Expectations
POZEN Inc. Reports Third-Quarter and Nine-Month Results
Get help downloading or viewing the above file types
Data provided by Nasdaq. Minimum 15 minutes delayed.